Protocol CAUSE-03 / CHEETAH

Asthma Clinical Trial

— CHEETAH  

Official title:

Mechanisms Underlying Asthma Symptoms and Exacerbations Examined Across T2 Status in Children (CHEETAH) (CAUSE-03)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06136091
• Other study ID #: DAIT CAUSE-03
• Status: Recruiting
• Start date: April 23, 2024
• Est. completion date: May 1, 2026

Study information

• Verified date: May 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old.

Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 310
• Est. completion date: May 1, 2026
• Est. primary completion date: May 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Participant and/or parent guardian must be able to understand and provide informed consent and assent

2. Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-03 Manual of Operations (MOP)

a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion

3. Either:

1. Have had a diagnosis of asthma made > 1 year prior to recruitment; participants who received an asthma diagnosis by a clinician <= 1 year prior to recruitment must report that their respiratory symptoms were present for more than 1 year prior to recruitment (asthma group), or

2. No report of ever being diagnosed with asthma (non-asthma group)

4. Either:

1. Require at least Step 2 therapy at the Screening/Enrollment Visit (asthma group), or

2. Have not used any asthma medications in the prior year (non-asthma group)

5. Are able to perform acceptable and repeatable spirometry per American Thoracic Society (ATS) criteria prior to enrollment

6. Have documentation of current medical insurance with prescription coverage at the Screening/Enrollment Visit

7. Participant and/or parent guardian has a smartphone compatible with the study electronic Patient Reported Outcomes (ePRO) system, Medidata Patient Cloud, and is willing to download one application for study use

Exclusion Criteria:

1. Parent or guardian is not able or willing to give written informed consent or comply with study protocol

2. Have concurrent medical problems that would require systemic corticosteroids or other immunomodulators during the study

3. Are currently receiving immunotherapy

4. Are currently receiving treatment with a biologic therapy or have received a biologic therapy within 3 months prior to enrollment

5. Are currently requiring greater than fluticasone 500 mcg bid plus Long-Acting Beta Agonists (LABA) one puff twice daily or its equivalent plus Long Acting Muscarinic Antagonists (LAMA) and/or individuals using oral corticosteroids daily or every other day for more than 14 days at the time of the Screening/Enrollment Visit

6. Are currently pregnant or lactating, or plan to become pregnant during the time of study participation. Females of child-bearing potential (post-menarche) must be abstinent or use a medically acceptable birth control method throughout the study (i.e., oral subcutaneous, mechanical, or surgical contraception)

7. Have a known, pre-existing clinically important lung condition other than asthma.

8. Have a current malignancy or previous history of cancer in remission for less than 12 months prior to enrollment

9. Have a known immunodeficiency disease

10. Use of investigational drugs within 4 weeks of enrollment

11. Have past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study

12. If in the asthma group, will not allow the study clinician, an asthma specialist, to manage their disease for the duration of the study or who are not willing to change their asthma medications to follow Protocol CAUSE-03 CHEETAH

13. If in the non-asthma group, having bronchodilator reversibility (improvement in Forced expiratory volume in 1 second (FEV1) with albuterol > = 10%) at the Screening/Enrollment visit

14. Have had a life-threatening asthma exacerbation in the last 2 years requiring intubation, mechanical ventilation or resulting in a hypoxic seizure. Potential participants may be reassessed as outlined in the Protocol CAUSE-03 Manual of Procedures (MOP)

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
United States	Children's Hospital Colorado: Allergy Program	Aurora	Colorado
United States	Boston Children's Hospital: Department of Immunology	Boston	Massachusetts
United States	Boston University School of Medicine: Pulmonary Center	Boston	Massachusetts
United States	Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center: Asthma Center	Cincinnati	Ohio
United States	Columbia University Medical Center: Division of Pediatric Pulmonology	New York	New York
United States	Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute	New York	New York
United States	Children's National Medical Center: Children's Research Institute	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asthma disease activity measured by the number of exacerbations during the 12-month observation period		Month 0 to Month 12
Secondary	Childhood Asthma Severity Index (CASI)	measured on a scale from 0 to 20 with smaller scores indicate a better outcome.	Month 0 to Month 12
Secondary	Modified Rhinitis Symptom Utility Index (MRSUI)	measured by assessing the frequency and severity (degree of bothering: not bothered, somewhat bothered, bothered a lot) of the participant's (1) stuffy or blocked nose, (2) runny nose, (3) sneezing, (4) itchy, watery eyes, and (5) itchy nose or throat over the preceding 14-day period	Month 0 to Month 12
Secondary	Wisconsin Upper Respiratory Symptom Survey for Kids (WURSS-K)	measured on a scale from 0 to 42 with higher scores indicating a worse outcome (high symptoms and high functional impairment)	Month 0 to Month 12
Secondary	Quality of life measured by the pediatric patient-reported (ages 8-17) or proxy-reported (ages 6-7) Patient-Reported Outcomes Measurement Information System (PROMIS) Asthma Impact Short Forms	The outcome measure is a score on a scale from 8 - 40 with higher scores indicating a worse outcome (more severe asthma symptoms).	Month 0 to Month 12
Secondary	Post-bronchodilator forced expiratory volume in 1 second (FEV1) for asthma group		Month 3 to Month 12
Secondary	Post-bronchodilator forced expiratory volume in 1 second (FEV1) for non-asthma group		At Month 0
Secondary	Post-bronchodilator forced vital capacity (FVC) for asthma group		Month 3 to Month 12
Secondary	Post-bronchodilator forced vital capacity (FVC) for non-asthma group		At Month 0
Secondary	Bronchodilator reversibility asthma group in the asthma group, measured by the percent change in FEV1 with albuterol		Month 3 to Month 12
Secondary	Bronchodilator reversibility in the non-asthma group, measured by the percent change in FEV1 with albuterol		At Month 0